Crux Wealth Advisors Reduces Stock Position in Johnson & Johnson $JNJ

Key Points

• Crux Wealth Advisors has significantly reduced its stake in Johnson & Johnson by 54.1%, now holding 1,946 shares valued at $297,000.
• Several institutional investors, including Chicago Partners Investment Group and Sigma Investment Counselors, have increased their holdings in Johnson & Johnson during the second quarter.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, set to be paid on December 9th, representing a 2.7% dividend yield.

Crux Wealth Advisors decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 54.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,946 shares of the company's stock after selling 2,296 shares during the quarter. Crux Wealth Advisors' holdings in Johnson & Johnson were worth $297,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Chicago Partners Investment Group LLC boosted its holdings in shares of Johnson & Johnson by 9.2% in the second quarter. Chicago Partners Investment Group LLC now owns 22,557 shares of the company's stock worth $3,814,000 after buying an additional 1,899 shares during the last quarter. Sigma Investment Counselors Inc. boosted its holdings in shares of Johnson & Johnson by 2.6% in the second quarter. Sigma Investment Counselors Inc. now owns 10,236 shares of the company's stock worth $1,564,000 after buying an additional 264 shares during the last quarter. Wingate Wealth Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 13.4% in the second quarter. Wingate Wealth Advisors Inc. now owns 1,828 shares of the company's stock worth $279,000 after buying an additional 216 shares during the last quarter. Planned Solutions Inc. boosted its holdings in shares of Johnson & Johnson by 2.3% in the second quarter. Planned Solutions Inc. now owns 4,148 shares of the company's stock worth $634,000 after buying an additional 93 shares during the last quarter. Finally, Financial Synergies Wealth Advisors Inc. purchased a new position in shares of Johnson & Johnson in the second quarter worth approximately $1,016,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Cowen reissued a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. UBS Group raised their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a "buy" rating in a research note on Tuesday, October 14th. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $200.06.

Johnson & Johnson Trading Up 0.3%

Johnson & Johnson stock opened at $193.78 on Tuesday. The stock has a market cap of $466.68 billion, a P/E ratio of 18.70, a PEG ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The firm's 50 day moving average price is $180.89 and its 200-day moving average price is $165.18.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.